44.48
0.48 (1.09%)
0.48 (1.09%)
Upgrade to Real-Time
Afterhours (Closed)
| Volume | 1,084,859 |
|
|||||
| News | - | ||||||
| Day High | 44.635 | Low High |
|||||
| Day Low | 43.46 | ||||||
Best deals to access real time data! |
|
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Halozyme Therapeutics Incorporated | HALO | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
 |
|
|---|---|---|---|---|
| 0.48 | 1.09% | 44.48 | 00:00:09 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 44.03 | 43.46 | 44.635 | 44.48 | 44.00 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 14,604 | 1,084,859 | $ 44.11 | $ 47,855,690 | - | 31.36 - 48.58 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:17:05 | 1 | $ 43.50 | USD |
Period:
Draw Mode:
Halozyme Therapeutics Incorporated Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 6.14B | 137.95M | 117.36M | $ 443.31M | $ 408.86M | 2.75 | 14.90 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | - | 8.20% |
Halozyme Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical HALO Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 47.50 | 48.54 | 43.46 | 45.92 | 1,594,009 | -3.02 | -6.36% |
| 1 Month | 45.53 | 48.54 | 42.18 | 45.18 | 1,170,419 | -1.05 | -2.31% |
| 3 Months | 41.53 | 48.58 | 36.95 | 43.44 | 1,105,379 | 2.95 | 7.1% |
| 6 Months | 39.80 | 48.58 | 31.36 | 39.79 | 997,328 | 4.68 | 11.76% |
| 1 Year | 45.53 | 48.58 | 31.36 | 39.47 | 901,157 | -1.05 | -2.31% |
| 3 Years | 17.52 | 56.40 | 12.71 | 31.41 | 1,199,392 | 26.96 | 153.88% |
| 5 Years | 12.86 | 56.40 | 11.41 | 26.67 | 1,090,523 | 31.62 | 245.88% |
Halozyme Therapeutics Description
| Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally. |